ICER: Ma­jor­i­ty of pay­er cov­er­age poli­cies sup­port 'key el­e­ments of fair ac­cess' in for­mu­la­ries

The cost-ef­fec­tive­ness watch­dog ICER took a look at 19 drugs and com­pared them to pay­er cov­er­age poli­cies — find­ing in its newest re­port that pay­ers, more of­ten than not, align with cer­tain cri­te­ria of fair ac­cess.

The 46-page fi­nal re­port pub­lished Tues­day ex­am­ined drugs such as Roche’s Hem­li­bra, J&J’s Rem­i­cade and Ste­lara, and Ab­b­Vie’s Hu­mi­ra and com­pared them to cov­er­age poli­cies from 18 for­mu­la­ries, in­clud­ing the 15 largest com­mer­cial for­mu­la­ries, the for­mu­la­ry for the Vet­er­ans Health Ad­min­is­tra­tion and the for­mu­la­ries of the two largest state ACA ex­change plans.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER